The protocol would incorporate the listed therapeutic agents in a combinatorial fashion and be applied following a confirmatory biopsy of HPV-oropharyngeal carcinoma (p16INK4a+/EZH2+ with high Ki-67 expression and mitotic progression) prior to the implementation of standard tumor board-recommended therapy for the individual patient. This evidence concerns the gene EZH2 and oropharyngeal carcinoma.